Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber. The committee voted 14 to 13 to advance Kennedy in a party-line vote around 10:30 a.m. ET.
Moderna and BioNTech shares fall after Senate committee vote RFK Jr.
Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% following the Senate Finance Committee's vote to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services to the full Senate.
Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...
BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance. See more on BNTX stock here.
A BioNTech spokesperson reaffirmed in an email on Jan. 3, 2025, that Sahin received his first dose of the vaccine at the beginning of 2021, adding, “His vaccination was administered using the ...
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...
BioNTech SE is advancing its oncology strategy with investigational therapies BNT327/PM8002 and mRNA cancer immunotherapy candidates to establish a new immuno-oncology backbone targeting a variety ...
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...
Shares of BioNTech fell 5.7% on Monday. Vaccine stocks are volatile after Moderna’s updated revenue guidance for 2025, which fell below analyst expectations. Get Pro-Level Earnings Insights ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing.com's Fair Value model demonstrated its effectiveness once again, identifying a significant opportunity in BioNTech SE (NASDAQ:BNTX) that resulted in a remarkable 51% return over just six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback